Want to see JP:4978 full AI Analyst Report?

ReproCELL Inc. (4978) Price & Analysis

0 Followers

4978 Stock Chart & Stats

¥143.00

¥3.00(2.91%)

At close: Jan 08 4:00 PM EST

¥143.00

¥3.00(2.91%)

Day’s Range― - ―

52-Week Range¥117.00 - ¥242.00

Previous CloseN/A

Volume331.50K

Average Volume (3M)510.74K

Market Cap

¥12.16B

Enterprise Value¥9.75B

Total Cash (Recent Filing)¥4.72B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta0.54

Next Earnings

Aug 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.32

Shares Outstanding98,079,890

10 Day Avg. Volume504,660

30 Day Avg. Volume510,736

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)1.88

Price to Sales (P/S)7.46

P/FCF Ratio-34.60

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)1.7

Revenue Forecast (FY)¥3.53B

Bulls Say, Bears Say

Bulls Say

Very Low Leverage / Strong Capital BufferNet-zero debt and a sizable, stable equity base provide durable financial flexibility: supports R&D funding, absorbs operating volatility, and reduces refinancing risk. Over a 2–6 month horizon this capital buffer underpins resilience and optionality for strategic investments or capital raises without pressuring creditors.

Solid Gross Profit BaseMaintaining >¥1.0B gross profit even amid top-line swings indicates the core product/service economics retain intrinsic value. This gross margin base can support recovery once operating expenses are managed, enabling sustainable margin improvement if revenue stabilizes or SG&A is optimized over the medium term.

Niche IPSC And Contract-service PositioningA focused business model in iPSC reagents and contract discovery services sits within growing, structural markets (regenerative medicine, drug discovery). These specialized offerings create repeatable service revenue opportunities and technical differentiation that support durable demand beyond short-term cycles.

Bears Say

Persistent Negative Free Cash FlowChronic negative operating and free cash flow means the business is not self-funding and requires external financing or equity dilution to sustain operations and R&D. Over 2–6 months this limits discretionary spend, constrains strategic execution, and raises financing and dilution risk if losses persist.

Revenue Volatility And Recent Sharp DeclineMeaningful swings in top-line make planning and investment decisions difficult; a ~21% annual revenue drop in 2026 signals fragility in demand or customer concentration. Sustained volatility undermines predictable margins and increases execution risk for scaling or cost structure adjustments in the medium term.

Profitability Erosion / Return To LossesThe swing back to sizable net losses and weak operating performance shows inconsistent ability to convert gross profits into operating income. This persistent profitability weakness raises execution risk, limits reinvestment capacity, and increases dependence on external capital to fund operations over the next several months.

4978 FAQ

What was ReproCELL Inc.’s price range in the past 12 months?

ReproCELL Inc. lowest stock price was ¥117.00 and its highest was ¥242.00 in the past 12 months.

What is ReproCELL Inc.’s market cap?

ReproCELL Inc.’s market cap is ¥12.16B.

When is ReproCELL Inc.’s upcoming earnings report date?

ReproCELL Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 36 days.

How were ReproCELL Inc.’s earnings last quarter?

ReproCELL Inc. released its earnings results on May 14, 2026. The company reported -¥1.4 earnings per share for the quarter, missing the consensus estimate of N/A by -¥1.4.

Is ReproCELL Inc. overvalued?

According to Wall Street analysts ReproCELL Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does ReproCELL Inc. pay dividends?

ReproCELL Inc. does not currently pay dividends.

What is ReproCELL Inc.’s EPS estimate?

ReproCELL Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does ReproCELL Inc. have?

ReproCELL Inc. has 98,079,890 shares outstanding.

What happened to ReproCELL Inc.’s price movement after its last earnings report?

ReproCELL Inc. reported an EPS of -¥1.4 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.775%.

Which hedge fund is a major shareholder of ReproCELL Inc.?

Currently, no hedge funds are holding shares in JP:4978

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

ReproCELL Inc.

Established in 2003 and headquartered in Yokohama, Japan, ReproCELL Incorporated operates as a prominent firm specializing in stem cell research. The company furnishes an extensive portfolio of products crucial for various stem cell applications, including a diverse array of specialized reagents for RNA reprogramming, cell growth (such as small molecules, growth factors, and cytokines), cell characterization (like antibodies and staining kits), cell culture (including pluripotent stem cell media and cell substrates), and cell handling (such as cryopreservation media, dissociation solutions, and transfection reagents). Furthermore, ReproCELL provides differentiated induced pluripotent stem cells (iPSCs), related components like feeder cells and induced neurons, 3D cell culture systems, and general laboratory consumables. Complementing its product lines, the company offers a comprehensive suite of services, spanning preclinical genomics, dedicated stem cell research, drug development support (encompassing efficacy, safety, and ADME analyses), access to human tissue samples, therapeutic pipeline development, and a range of clinical services, including laboratory diagnostics and the creation of GMP iPSC master cell banks.